Pain for big Indian pharma companies continue warns CRISIL, as FDA woes remains unresolved

Indian drug makers in the last few years have diversified their portfolio towards complex generics in an attempt to insulate themselves from pricing pressure in the US. The complex generic pipeline of Indian generic makers stands at 25%, it is this pipeline that is expected to pump up the sales numbers for Indian companies.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news